European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live06-22

European equities traded in the US as American depositary receipts started the week higher late Monday morning, advancing 0.61% to 1,903.57 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and telecommunications company Nokia (NOK), which rose 4.5% and 4.2% respectively. They were followed by internet browser company Opera (OPRA) and biopharmaceutical company DBV Technologies (DBVT), which were up 2.8% and 1.8% respectively.

The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and pharmaceutical company Sanofi (SNY), which fell 5% and 2.8% respectively. They were followed by internet advertising firm Criteo (CRTO) and semiconductor company Sequans Communications (SQNS), which were down 2.6% and 2.4% respectively.

The gainers from the UK were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Amarin (AMRN), which advanced 5.7% and 4.6% respectively. They were followed by lenders Lloyds Banking Group (LYG) and Barclays (BCS), which increased 4% and 3.8% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company NuCana (NCNA) and mining company BHP Group (BHP), which lost 3.1% and 2% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and medical device maker Smith & Nephew (SNN), which dropped 1.8% and 0.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment